no accompanying substance use disorder is no ted (e.g., F16.980 psilocybin-induced anxi-
ety disorder, with onset during intoxication).  When more than one substance is judged to
play a significant role in the development of  anxiety symptoms, each should be listed sep-
arately (e.g., F15.280 severe methylphenidate use disorder with methylphenidate-induced
anxiety disorder, with onset during intoxica tion; F19.980 salbutamol-induced anxiety dis-
order, with onset after medication use).
Diagnostic Features
The essential features of substance/medicati on-induced anxiety di sorder are prominent
symptoms of panic or anxiety (Criterion A) that  are judged to be due to the effects of a sub-
stance (e.g., a drug of abuse, a medication, or  a toxin exposure). The panic or anxiety symp-
toms must have developed duri ng or soon after substance in toxication or withdrawal or
after exposure to a medication, and the substa nces or medications must be capable of pro-
ducing the symptoms (Criteri on B2). Substance/medication-induced anxiety disorder
due to a prescribed treatment for a mental disorder or another medical condition must
have its onset while the individual is receivin g the medication (or during withdrawal, if a
withdrawal is associated with the medication ). Once the treatment is discontinued, the
panic or anxiety symptoms will usually improv e or remit within days to several weeks to
a month (depending on the half-life of the su bstance/medication and the presence of with-
drawal). The diagnosis of substance/medicati on-induced anxiety disorder should not be
given if the onset of the panic or anxiety symptoms precedes the substance/medication in-